ImmunoGen commercial chief to withdraw before drug launch

With less than a month to go before a scheduled regulatory decision on its lead asset, clinical-stage biotech ImmunoGen said its SVP/chief commercial officer, Kristen Harrington-Smith, will step down from her post.

The company is developing mirvetuximab soravtansine, an antibody drug conjugate, in ovarian cancer patients who express high levels of folate receptor alpha (FRα) and who are resistant to chemotherapy. The agent is under priority review at the Food and Drug Administration and has a PDUFA date of November 28.